Published: May 17, 2021
International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease
Clene anticipates the expansion of disease indications for CNM-Au8 beyond amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis
SALT LAKE CITY, May 17, 2021 (GLOBE NEWSWIRE)
Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary
Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, received a Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine (NAM) to accelerate the preclinical development of CNM-Au8, a bioenergetic nanocatalyst, for treatment of neuronal aging-related deficits and Alzheimer’s disease. The Healthy Longevity Global Competition was founded in 2019
United-states
Maryland
Austria
Salt-lake-city
Utah
Americans
Gwendolyn-schanker
Jerome-mertens
Bruce-mackle
Rob-etherington
Us-national-academy-of-medicine
Lifesci-advisors